Monovalent Fucose-Binding Peptide for HCC Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for detecting hepatocellular carcinoma (HCC) such as alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) have limited diagnostic sensitivity and specificity, and existing methods like ultrasound are costly and ineffective at early detection, necessitating a more effective method for identifying HCC.
Innovation Solution
A method involving a monovalent fucose-binding peptide with at least 80% identity to a specific peptide sequence, immobilized on a solid phase, is used to detect fucosylated alpha1-acid glycoprotein (AGP) in samples, allowing for the assessment of HCC risk through increased concentration comparison with reference concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If AFP or DCP are used as biomarkers for HCC detection, then the diagnostic process is simple and inexpensive, but the diagnostic sensitivity and specificity are insufficient
Solution Approach 1:
The invention segments the detection process by first capturing fucosylated glycoproteins using AAL lectin, then specifically detecting AGP among the captured proteins. This two-stage approach separates the enrichment step from the specific detection step, allowing for higher precision while maintaining reasonable complexity
Solution Approach 2:
The AAL lectin acts as an intermediary that captures fucosylated glycoproteins from the sample, enabling subsequent specific detection of AGP. This intermediary step enriches the target analytes and improves detection sensitivity without requiring direct complex assays
2Measurement precision
If AAL lectin is used to detect fucosylated glycoproteins, then the detection of HCC-associated fucosylation is enhanced, but the ability to differentiate between HCC and cirrhosis is reduced due to broad specificity
Solution Approach 1:
The invention segments the detection by first using AAL to capture all fucosylated glycoproteins, then applying a second antibody specifically against AGP. This segmentation allows enrichment of fucosylated proteins followed by specific identification of HCC-associated AGP, improving differentiation capability
Solution Approach 2:
The invention applies different specificity requirements to different stages of detection: AAL provides broad fucose-binding capability at the enrichment stage, while the anti-AGP antibody provides specific HCC-related detection at the measurement stage, optimizing both sensitivity and specificity for different purposes
3Measurement precision
If ultrasound is used for HCC detection, then the diagnostic sensitivity and specificity improve to 60-80%, but the cost increases and early stage detection remains limited
Solution Approach 1:
The invention replaces the mechanical ultrasound imaging system with a biochemical assay system using lectin binding and antibody detection. This substitution enables detection of molecular biomarkers (fucosylated AGP) that indicate early HCC development, potentially achieving comparable or superior sensitivity at lower cost
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides improved diagnostic specificity and sensitivity for differentiating HCC from cirrhosis and hepatitis, enhancing early detection capabilities and reducing costs compared to existing methods.
Implementation Method 1
AAL displays a broad specificity for fucosylated oligosaccharides and binds to oligosaccharides with fucose linked α1-6, α1-2, α1-3 and α1-4
Data Source
AI summary
The present invention relates to a method for detecting fucosylated alpha1-acid glycoprotein (AGP) in a sample, comprising the steps providing a monovalent fucose-binding peptide having at least 80% identity, such as 85, 90, 95, 99 or 100% identity, to a peptide having an amino acid according to SEQ ID NO: 1, immobilised on a solid phase; bringing the sample into contact with the immobilised fucose-binding peptide; and detecting any fucosylated AGP bound to said fucose-binding peptide. The invention further relates to a method for assessing a risk that a human individual suffers from hepatocellular carcinoma, and to a kit of parts and antibodies useful in the methods according to the invention, and to a peptide useful as an immunizing antigen in production of such antibodies.